A Phase 3 interventional study of Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) and Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck) in Varicella, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 14th largest by enrollment, is one of 3 that started in 2009, is one of 12 in phase 3, and was the 9th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
28 studies in Chickenpox by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 28 studies in Chickenpox by Merck & Co., Inc, this one is the 17th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2009, is one of 21 in phase 3, and was the 14th registered.
Merck & Co., Inc’s Chickenpox studies by the year they started, since 1995.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 28 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.
This treatment has been approved for sale to the public.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) · Biological: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
Biological: Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck) · Biological: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
Drug page: Chickenpox Vaccine
VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
Drug page: Chickenpox Vaccine
VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).
Percent of participants with varicella antibody titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer \< 1.25 gpELISA units/mL. Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.
Time frame: 6 weeks following first vaccination
| Milestone | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II |
|---|---|---|
| Started | 299 | 299 |
| Completed | 274 | 273 |
| Not completed | 25 | 26 |
| Withdrew: Not vaccinated | 3 | 0 |
| Withdrew: Withdrawal by subject | 13 | 14 |
| Withdrew: Lost to follow-up | 9 | 12 |
| Milestone | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II |
|---|---|---|
| Started | 274 | 273 |
| Completed | 270 | 262 |
| Not completed | 4 | 11 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 9 |
Percent of participants with varicella antibody titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer \< 1.25 gpELISA units/mL. Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.
| Percent of participants | VARIVAX 2007 Process + M-M-R II |
|---|---|
| Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process). | 96.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VARIVAX 2007 Process + M-M-R II | — | 1/296 (0.3%) | 189/296 (63.9%) |
| VARIVAX 1999 Process + M-M-R II | — | 1/299 (0.3%) | 156/299 (52.2%) |
| Event | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II |
|---|---|---|
| Croup infectiousInfections and infestations | 1/296 | 0/299 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 0/296 | 1/299 |
| Event | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II |
|---|---|---|
| Injection site painGeneral disorders | 84/296 | 70/299 |
| PyrexiaGeneral disorders | 74/296 | 65/299 |
| Injection site erythemaGeneral disorders | 67/296 | 64/299 |
| Injection site swellingGeneral disorders | 32/296 | 35/299 |
| Otitis mediaInfections and infestations | 31/296 | 22/299 |
| IrritabilityGeneral disorders | 27/296 | 15/299 |
| DiarrhoeaGastrointestinal disorders | 24/296 | 17/299 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 21/296 | 15/299 |
| VomitingGastrointestinal disorders | 20/296 | 13/299 |
| Upper respiratory tract infectionInfections and infestations | 20/296 | 20/299 |
| Age, Continuous(months) | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II | Total |
|---|---|---|---|
| Mean | 13.0 ± 1.83 | 13.0 ± 1.83 | 13.0 ± 1.83 |
| Sex: Female, Male(Participants) | VARIVAX 2007 Process + M-M-R II | VARIVAX 1999 Process + M-M-R II | Total |
|---|---|---|---|
| Female | 158 | 138 | 296 |
| Male | 141 | 161 | 302 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Jan 2009, a primary completion of Oct 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine